T. Rowe Price Associates
IMDX

T. Rowe Price Associates’s Insight Molecular Diagnostics IMDX Stock Holding History

T. Rowe Price Associates’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,830
Closed -$27K – 2966
2022
Q3 		$27K Hold
1,830
– – ﹤0.01% 2899
2022
Q2 		$33K Sell
1,830
-249
-12% -$5.66K ﹤0.01% 2902
2022
Q1 		$62K Buy
2,079
+725
+54% +$23.2K ﹤0.01% 2905
2021
Q4 		$59K Sell
1,354
-100
-7% -$5.75K ﹤0.01% 2919
2021
Q3 		$104K Buy
1,454
+10
+0.7% +$919 ﹤0.01% 2838
2021
Q2 		$166K Sell
1,444
-920
-39% -$89.8K ﹤0.01% 2767
2021
Q1 		$245K Buy
+2,364
New +$224K ﹤0.01% 2628

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's IMDX Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 1,830 shares — an estimated $27K sold.

T. Rowe Price Associates first reported a position in IMDX in Q1 2021 and held it in 7 quarters. The position peaked at $245K in Q1 2021. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,830 Insight Molecular Diagnostics shares in Q4 2022, an estimated $27K.
  • T. Rowe Price Associates first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 7 quarters.
  • T. Rowe Price Associates's Insight Molecular Diagnostics position peaked at $245K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.